Vivalis opens new lab for antibody discovery; posts 112% revenue hike

25 January 2012

French biotech firm Vivalis (NNYSE Euronext: VLS) says it has opened a new facility for partnered VIVA|Screen programs, a potent technology for the discovery of fully-human monoclonal antibodies using a combination of two technologies acquired by Vivalis, in the Lyon Gerland Biotechnology Cluster.

The Gerland biotechnology district offers the advantages of a centralized, world-class research and production environment in human and animal health, Vivalis noted. Resident companies include the likes of Sanofi Pasteur, Merial and Genzyme, along with research institutions such as the French Institute for Protein Biology and Chemistry.

With this new state-of-the-art laboratory, Vivalis says it will be able to expand its research and development capacity and strengthen the VIVAA|Screen platform in current and future industrial collaborations. The company recently expanded its collaboration with Sanofi Pasteur for the discovery of a fully human monoclonal antibody (MAb) against an additional undisclosed infectious disease target (The Pharma Letter January 19).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK